SERTANTY SIGNS COLLABORATION AND SERVICE AGREEMENT WITH SPECS
San Jose, California, December 9, 2004 - Sertanty, Inc., a leading provider of drug discovery cheminformatics products and services, and Specs, a leading supplier of screening compounds and research chemicals, announced today the signing of a collaboration and service agreement to design and produce small molecule libraries targeting several kinase families. Under the agreement, Sertanty will apply its Kinase KnowledgeBase and predictive eScreen technology to design targeted libraries that Specs will offer to its worldwide customerbase of pharmaceutical and biotechnology companies.
Dr. Steven Muskal, CEO of Sertanty, said, "We are very excited to be working with Specs, a premier chemistry partner of the pharmaceutical industry, to provide targeted, drug-like molecules customized to enhance the output of drug discovery efforts. Specs' chemical production and provision know-how is an excellent synergistic match to Sertanty's technology and design capabilities."
"We are delighted to collaborate with Sertanty on the design and production of kinase targeted libraries", said Dr.
Sertanty, Inc., is headquartered in